Overview

Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
This study aims to compare the efficacy and safety of lenalidomide plus CHOP (L-CHOP) versus CHOP alone in patients with previously untreated peripheral T-cell lymphoma (PTCL)
Phase:
Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators:
Changhai Hospital
First Affiliated Hospital of Harbin Medical University
First Affiliated Hospital Xi'an Jiaotong University
First Hospital of China Medical University
Henan Provincial People's Hospital
Huashan Hospital
Hunan Cancer Hospital
Jilin Provincial Tumor Hospital
RenJi Hospital
Ruijin Hospital
Shandong Provincial Hospital
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Shanxi Province Cancer Hospital
Southern Medical University, China
The Affiliated Hospital of Xuzhou Medical University
The First Affiliated Hospital of Anhui Medical University
The First Affiliated Hospital of Dalian Medical University
Union hospital of Fujian Medical University
Wuhan Union Hospital, China
Xiangya Hospital of Central South University
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Xinqiao Hospital of Chongqing
Zhongda Hospital
Zhongshan Hospital Xiamen University
Treatments:
Cyclophosphamide
Doxorubicin
Lenalidomide
Prednisone
Vincristine